Endocrine therapy for hormone treatment-naïve advanced breast cancer

Area of Science:

• Oncology
• Endocrinology
• Clinical Pharmacology

Background:

• A subset of patients with hormone receptor-positive locally advanced or metastatic breast cancer have not received prior endocrine therapy.
• Clinical data specifically evaluating endocrine therapies in this endocrine therapy-naïve patient population are limited.

Purpose of the Study:

• To review randomized phase II and III clinical studies of anastrozole, letrozole, exemestane, palbociclib, and fulvestrant.
• To determine the evidence base supporting the use of specific endocrine therapies in endocrine therapy-naïve patients with hormone receptor-positive locally advanced or metastatic breast cancer.

Main Methods:

• Systematic review of randomized phase II and III clinical trials.
• Inclusion criteria focused on studies involving anastrozole, letrozole, exemestane, palbociclib, and fulvestrant.
• Analysis of data pertaining to patients with and without prior endocrine therapy.

Main Results:

• A paucity of clinical studies specifically addressing endocrine therapy-naïve patients was identified.
• First-line treatment effects for endocrine therapies appear consistent between patients who have and have not received prior endocrine treatment.
• Evidence suggests comparable efficacy of first-line endocrine agents in both patient groups.

Conclusions:

• Despite limited dedicated studies, current evidence suggests that first-line endocrine therapies demonstrate consistent treatment effects in endocrine therapy-naïve patients.
• The findings support the use of established endocrine agents as first-line treatment options for this patient population.
• Further research may be warranted to specifically confirm these observations in larger, dedicated trials.